March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Risk Of Cataract In Persons With Acquired Immune Deficiency Syndrome And Cytomegalovirus Retinitis
Author Affiliations & Notes
  • Elizabeth A. Sugar
    Biostatistics, Epidemiology, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland
    The Sidney Kimmel Comprehensive Cancer Center,
    The Johns Hopkins University School of Medicine, Baltimore, Maryland
  • Alice T. Lyon
    Ophthalmology, Northwestern University, Chicago, Illinois
  • Richard A. Lewis
    Ophthalmology, Medicine, Pediatrics, Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
  • Douglas A. Jabs
    Ophthalmology, Internal Medicine, Mount Sinai School of Medicine, New York, New York
  • Murk-Hein Heinemann
    Ophthalmology, Weill Cornell Medical College, New York, New York
    Opthalmic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
  • James P. Dunn
    Ophthalmology,
    The Johns Hopkins University School of Medicine, Baltimore, Maryland
  • John H. Kempen
    Ophthalmology, Epidemiology, Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
  • Studies of Ocular Complications of AIDS Research Group
    Biostatistics, Epidemiology, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  Elizabeth A. Sugar, None; Alice T. Lyon, None; Richard A. Lewis, None; Douglas A. Jabs, Abbott Laboratories (C), Alcon Laboratories (C), Allergan Pharmaceutical Corporation (C), Applied Genetic Technologies Corporation (S), Corcept Theraputics (C), GenenTech, Inc (C), Genzyme Corporation (C), GlaxoSmithKline (C), Novartis Pharmaceuticals Corporation (C), Roche Pharmaceuticals (C); Murk-Hein Heinemann, None; James P. Dunn, None; John H. Kempen, Alcon (C), Allergan (C), Harbor Biosciences (C), Lux Biosciences (C), Sanofi Pasteur (C)
  • Footnotes
    Support  NEI Grants U10 EY 08052, U10 EY 08057, and U10 EY 08067
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6218. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elizabeth A. Sugar, Alice T. Lyon, Richard A. Lewis, Douglas A. Jabs, Murk-Hein Heinemann, James P. Dunn, John H. Kempen, Studies of Ocular Complications of AIDS Research Group; Risk Of Cataract In Persons With Acquired Immune Deficiency Syndrome And Cytomegalovirus Retinitis. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6218.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To evaluate the prevalence and incidence of cataract, and the associated risk factors, in the eyes of patients with acquired immune deficiency syndrome (AIDS) and cytomegalovirus retinitis (CMVR).

 
Methods:
 

Demographic, clinical, and treatment characteristics were recorded quarterly for 489 patients (729 eyes) with CMVR in the Longitudinal Study of the Complications of AIDS. Eyes were identified as having cataract if they underwent cataract surgery or had a high grade of lens opacity by biomicroscopy that was determined to cause a reduction in visual acuity to worse than 20/40.

 
Results:
 

Overall, 144 (20%) of eyes with CMVR had prevalent cataract and 145 incident cases were observed. Individuals with bilateral CMVR had a higher prevalence of cataract than those with unilateral disease (adjusted odds ratio [aOR] = 2.7, p < 0.001). For those with unilateral disease, the eye with CMVR was more likely to have a cataract than the fellow eye without retinitis (15% vs 1.4%, p < 0.001). The age-adjusted prevalence was significantly higher than that of a comparable population-based study (p < 0.001). A history of retinal detachment was associated with increased incidence (adjusted hazard ratio [aHR]=14.5, p < 0.001, if repaired with silicone oil and aHR = 2.5, p < 0.001, otherwise). As the fraction of retinal involvement in CMVR lesions increased, the risk of cataract increased (aHR=2.1, p < 0.001, for 25-49% and aHR = 4.4, p < 0.001, for ≥ 50% as compared to ≤ 24% involvement). Anterior inflammation (aHR = 2.1, p < 0.001) and a history of cataract in the contralateral eye (aHR: 2.1, p < 0.001) also were associated with increased incidence. These factors also were risk factors for prevalent cataract, as were increased age (aOR = 11.5, p =0.003, for age ≥60 years versus less than 40) and time since CMVR diagnosis (aOR = 1.4, p < 0.001). Ganciclovir implants did not significantly increase the incidence (aHR = 1.3, 95% confidence interval: 0.8 to 1.9, p = 0.17).

 
Conclusions:
 

Eyes with CMV retinitis are at high risk to develop cataracts. Some of the risk factors (large retinal lesion size and use of silicone oil in retinal detachment repair) are potentially modifiable, albeit not in all cases. Given the high prevalence and incidence rates, cataract is likely to be an important cause of visual acuity loss in a population with AIDS and CMVR.

 
Keywords: cataract • cytomegalovirus • AIDS/HIV 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×